Base de dados : MEDLINE
Pesquisa : N03.219.151.165 [Categoria DeCS]
Referências encontradas : 22429 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2243 ir para página                         

  1 / 22429 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460083
[Au] Autor:Rendas-Baum R; Kosinski M; Singh A; Mebus CA; Wilkinson BE; Wallenstein GV
[Ad] Endereço:QualityMetric Incorporated Lincoln, RI.
[Ti] Título:Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.
[So] Source:Rheumatology (Oxford);56(8):1386-1394, 2017 Aug 01.
[Is] ISSN:1462-0332
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Objectives: RA causes high disability levels and reduces health-related quality of life, triggering increased costs and risk of unemployment. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. These post hoc analyses of phase 3 data aimed to assess monthly medical expenditure (MME) and risk of job loss for tofacitinib treatment vs placebo. Methods: Data analysed were from two randomized phase 3 studies of RA patients (n = 1115) with inadequate response to MTX or TNF inhibitors (TNFi) receiving tofacitinib 5 or 10 mg twice daily, adalimumab (one study only) or placebo, in combination with MTX. Short Form 36 version 2 Health Survey physical and mental component summary scores were translated into predicted MME via an algorithm and concurrent inability to work and job loss risks at 6, 12 and 24 months, using Medical Outcomes Study data. Results: MME reduction by month 3 was $100 greater for tofacitinib- than placebo-treated TNFi inadequate responders (P < 0.001); >20 and 6% reductions from baseline, respectively. By month 3 of tofacitinib treatment, the odds of inability to work decreased ⩾16%, and risk of future job loss decreased ∼20% (P < 0.001 vs placebo). MME reduction by month 3 was $70 greater for tofacitinib- than placebo-treated MTX inadequate responders (P < 0.001); ⩾23 and 13% reductions from baseline, respectively. By month 3 of tofacitinib treatment, the odds of inability to work decreased ⩾31% and risk of future job loss decreased ⩾25% (P < 0.001 vs placebo). Conclusion: Tofacitinib treatment had a positive impact on estimated medical expenditure and risk of job loss for RA patients with inadequate response to MTX or TNFi.
[Mh] Termos MeSH primário: Antirreumáticos/economia
Artrite Reumatoide/economia
Efeitos Psicossociais da Doença
Gastos em Saúde
Piperidinas/economia
Pirimidinas/economia
Pirróis/economia
Retorno ao Trabalho/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adalimumab/administração & dosagem
Adalimumab/economia
Adulto
Antirreumáticos/administração & dosagem
Artrite Reumatoide/tratamento farmacológico
Método Duplo-Cego
Quimioterapia Combinada
Feminino
Seres Humanos
Masculino
Metotrexato/administração & dosagem
Metotrexato/economia
Meia-Idade
Piperidinas/administração & dosagem
Pirimidinas/administração & dosagem
Pirróis/administração & dosagem
Fatores de Risco
Resultado do Tratamento
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE III; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antirheumatic Agents); 0 (Piperidines); 0 (Pyrimidines); 0 (Pyrroles); 87LA6FU830 (tofacitinib); FYS6T7F842 (Adalimumab); YL5FZ2Y5U1 (Methotrexate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170502
[St] Status:MEDLINE
[do] DOI:10.1093/rheumatology/kex087


  2 / 22429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29267411
[Au] Autor:Dewa CS
[Ad] Endereço:Department of Psychiatry and Behavioral Sciences, University of California, Davis.
[Ti] Título:[The Costs of Mental Disorders in the Workplace: Can They Be Decreased?]
[Ti] Título:Les coûts des troubles mentaux en milieu de travail peuvent-ils être réduits ?.
[So] Source:Sante Ment Que;42(2):31-38, 2017.
[Is] ISSN:0383-6320
[Cp] País de publicação:Canada
[La] Idioma:fre
[Ab] Resumo:Objectives The World Economic Forum estimated that, by 2030, global costs of mental disorders are projected to reach US$6.0 trillion; about two thirds of these costs will be attributed to lost productivity related to disability. This brief article discusses factors that are related to the costs of mental illness in the workplace, identifies some of the workplace elements which could be targeted to reduce costs and explores examples of types of workplace interventions that can reduce costs.Methods We summarize the results of a Canadian research program using economic analyses to understand the costs of work disability related to mental disorders and cost-effective interventions.Results There are at least two main approaches to decrease the costs of mental disorders in the workplace. The first approach could be to decrease the prevalence of mental disorders among workers or the incidence of sickness absences. A second approach would be to increase access to treatment by addressing barriers to treatment. Both can have significant impacts to decrease costs.Conclusions Treatment can help workers experience mental disorders have higher productivity than they would have otherwise. By creating supportive workplace cultures through management training, organizations can potentially see a return through decreased sickness absences and higher productivity.
[Mh] Termos MeSH primário: Efeitos Psicossociais da Doença
Transtornos Mentais/economia
Local de Trabalho
[Mh] Termos MeSH secundário: Redução de Custos
Seres Humanos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE


  3 / 22429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28741257
[Au] Autor:Joshi S; Rizzoli P; Loder E
[Ad] Endereço:Clinical Pharmacy Practice, MCPHS University College of Pharmacy, Worcester, USA.
[Ti] Título:The comorbidity burden of patients with cluster headache: a population-based study.
[So] Source:J Headache Pain;18(1):76, 2017 Dec.
[Is] ISSN:1129-2377
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Evidence is limited regarding the comorbidity burden of patients with cluster headache (CH). We aimed to characterize comorbid conditions in a cohort of CH patients diagnosed by headache experts, using electronic health record information from the Partners Research Patient Data Registry (RPDR). METHODS: We identified and reviewed the charts of unique patients diagnosed by headache specialists over an 11-year period, and a set of matched controls. Patients were categorized as having Definite, Unconfirmed or no CH. We calculated the prevalence of and tested for statistically significant differences of selected comorbid conditions in these populations. RESULTS: An RPDR query identified 170 patients with a free text or ICD diagnosis of cluster headache. 15 records belonging to Partners employees were excluded. 75 patients met diagnostic criteria for CH (Definite CH). 22 had headaches with some features of CH but the diagnosis was uncertain (Unconfirmed CH). In 58 the diagnosis was determined to be inaccurate due to data entry errors. Patients with Definite CH had an average age of 43.4 years; 80% were male. The average time from CH onset to diagnosis was 12.7 years (range 1-51). The average number of yearly emergency department and outpatient visits for the group of Definite CH patients was 4.5 and 25.4, respectively, compared with 1.1 and 6.9 in controls. Of the 55 examined conditions, four were statistically significantly less common in patients with definite CH compared with controls (diabetes, musculoskeletal/orthopaedic problems, "other gastrointestinal diagnoses" and skin conditions) and four were statistically significantly more common (smoking, depression, dental disorders and deviated septum). CONCLUSIONS: In this large population-based study, we identified a surprisingly small number of patients who met strict diagnostic criteria for CH. In these patients, however, we identified a distinct pattern of selected comorbidities. The pattern is somewhat but not entirely consistent with that of the "classic" CH patient depicted in the medical literature. CH patients are frequently diagnosed with sinus or dental problems. Many experience substantial delay in receiving a diagnosis. These things may in part explain the high frequency of medical visits in this population. It is difficult to distinguish conditions that are genuinely comorbid with CH from those that reflect misdiagnoses or medical scrutiny of patients in frequent contact with the healthcare system.
[Mh] Termos MeSH primário: Cefaleia Histamínica/diagnóstico
Cefaleia Histamínica/epidemiologia
Efeitos Psicossociais da Doença
Vigilância da População
[Mh] Termos MeSH secundário: Adulto
Idoso
Estudos de Coortes
Comorbidade
Erros de Diagnóstico
Registros Eletrônicos de Saúde/tendências
Feminino
Seres Humanos
Masculino
Transtornos Mentais/diagnóstico
Transtornos Mentais/epidemiologia
Meia-Idade
Vigilância da População/métodos
Prevalência
Sistema de Registros
Fumar/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170726
[St] Status:MEDLINE
[do] DOI:10.1186/s10194-017-0785-3


  4 / 22429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29419385
[Au] Autor:Capewell S; Cairney P; Clarke A
[Ad] Endereço:Public Health and Policy, Institute of Psychology Health and Society, University of Liverpool, Liverpool, UK.
[Ti] Título:Should action take priority over further research on public health?
[So] Source:BMJ;360:k292, 2018 02 01.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Prática Clínica Baseada em Evidências/métodos
Promoção da Saúde/métodos
Saúde Pública/normas
Pesquisa
[Mh] Termos MeSH secundário: Efeitos Psicossociais da Doença
Seres Humanos
Política Nutricional/tendências
Formulação de Políticas
Controle Social Formal
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k292


  5 / 22429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29181930
[Au] Autor:Skråning S; Lindskog BV
[Ti] Título:The Zika outbreak in Brazil: An unequal burden..
[So] Source:Tidsskr Nor Laegeforen;137(22), 2017 11 28.
[Is] ISSN:0807-7096
[Cp] País de publicação:Norway
[La] Idioma:nor
[Mh] Termos MeSH primário: Efeitos Psicossociais da Doença
Microcefalia
Infecção pelo Zika virus
[Mh] Termos MeSH secundário: Brasil/epidemiologia
Assistência à Saúde/organização & administração
Surtos de Doenças/economia
Feminino
Saúde Global
Acesso aos Serviços de Saúde
Seres Humanos
Recém-Nascido
Microcefalia/economia
Microcefalia/virologia
Mães/psicologia
Saúde Única
Pobreza
Gravidez
Complicações Infecciosas na Gravidez/economia
Complicações Infecciosas na Gravidez/epidemiologia
Complicações Infecciosas na Gravidez/virologia
Previdência Social
Saúde da Mulher
Zika virus/isolamento & purificação
Infecção pelo Zika virus/congênito
Infecção pelo Zika virus/economia
Infecção pelo Zika virus/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.4045/tidsskr.17.0655


  6 / 22429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29300998
[Au] Autor:Reusch JEB; Kumar TR; Regensteiner JG; Zeitler PS; Conference Participants
[Ad] Endereço:Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
[Ti] Título:Identifying the Critical Gaps in Research on Sex Differences in Metabolism Across the Life Span.
[So] Source:Endocrinology;159(1):9-19, 2018 01 01.
[Is] ISSN:1945-7170
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The National Institutes of Health (NIH) Office of Research in Women's Health now functions under a mandate calling for the systematic inclusion of both female and male cells, animals, and human subjects in all types of research, so that sex as a biological variable is understood in health and disease. Sex-specific data can improve disease prevention, diagnosis, and treatment as well as reduce inequities. Inclusion of women in research studies has modestly improved over the last 20 years, yet preclinical research is still primarily done using male animal models and male-derived cells, with the result that many conclusions are made based on incomplete and sex-biased data. There are important, yet poorly studied, sex differences in cardiometabolic disease. To begin to address these sex differences, the Center for Women's Health Research at the University of Colorado held its inaugural National Conference, "Sex Differences Across the Lifespan: A Focus on Metabolism," in September 2016 (cwhr@ucdenver.edu). Research to address the important goal of understanding key sex differences in cardiometabolic disease across the life span is lacking. The goal of this article is to discuss the current state of research addressing sex differences in cardiometabolic health across the life span, to outline critical research gaps that must be addressed in response to NIH mandates, and, importantly, to develop strategies to address sex as a biological variable to understand disease mechanisms as well as develop diagnostic and therapeutic modalities.
[Mh] Termos MeSH primário: Envelhecimento
Pesquisa Biomédica/métodos
Metabolômica/métodos
Determinação de Necessidades de Cuidados de Saúde
Saúde da Mulher
[Mh] Termos MeSH secundário: Animais
Pesquisa Biomédica/tendências
Doenças Cardiovasculares/epidemiologia
Doenças Cardiovasculares/fisiopatologia
Doenças Cardiovasculares/prevenção & controle
Doenças Cardiovasculares/terapia
Congressos como Assunto
Efeitos Psicossociais da Doença
Feminino
Seres Humanos
Masculino
Metabolômica/tendências
National Institutes of Health (U.S.)
Gravidez
Caracteres Sexuais
Fatores Sexuais
Estados Unidos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180228
[Lr] Data última revisão:
180228
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180105
[St] Status:MEDLINE
[do] DOI:10.1210/en.2017-03019


  7 / 22429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28470892
[Au] Autor:Berk L; Hallam KT; Venugopal K; Lewis AJ; Austin DW; Kulkarni J; Dodd S; de Castella A; Fitzgerald PB; Berk M
[Ad] Endereço:Deakin University, IMPACT Strategic Research Centre, School of Medicine, Barwon Health, Geelong, Vic., Australia.
[Ti] Título:Impact of irritability: a 2-year observational study of outpatients with bipolar I or schizoaffective disorder.
[So] Source:Bipolar Disord;19(3):184-197, 2017 May.
[Is] ISSN:1399-5618
[Cp] País de publicação:Denmark
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Many people experience irritability when manic, hypomanic, or depressed, yet its impact on illness severity and quality of life in bipolar and schizoaffective disorders is poorly understood. This study aimed to examine the relationship between irritability and symptom burden, functioning, quality of life, social support, suicidality, and overall illness severity in a naturalistic cohort of people with bipolar I or schizoaffective disorder. METHODS: We used data from 239 adult outpatients with bipolar I or schizoaffective disorder in the Bipolar Comprehensive Outcomes Study (BCOS) - a non-interventional observational study with a 2-year follow-up period. Baseline demographic and clinical characteristics of participants with and without irritability were compared. A mixed-model repeated measures analysis was conducted to examine the longitudinal effect of irritability on clinical and quality-of-life variables over follow-up using significant baseline variables. RESULTS: At baseline, 54% of participants were irritable. Baseline irritability was associated with illness severity, mania, depression, psychotic symptoms, suicidality, poor functioning, and quality of life, but not diagnosis (schizoaffective/bipolar disorder). Participants with irritability were less likely to have a partner and perceived less adequate social support. On average, over follow-up, those with irritability reported more symptoms, functional impairment, and suicidality. Furthermore, the effects of irritability could not be fully explained by illness severity. CONCLUSIONS: Irritability was associated with more negative symptomatic, functional, and quality-of-life outcomes and suicidality. The identification, monitoring, and targeted treatment of irritability may be worth considering, to enhance health and wellbeing outcomes for adults with bipolar and schizoaffective disorders.
[Mh] Termos MeSH primário: Transtorno Bipolar
Humor Irritável
Transtornos Psicóticos
Qualidade de Vida
[Mh] Termos MeSH secundário: Atividades Cotidianas/psicologia
Adulto
Austrália/epidemiologia
Transtorno Bipolar/diagnóstico
Transtorno Bipolar/epidemiologia
Transtorno Bipolar/psicologia
Estudos de Coortes
Efeitos Psicossociais da Doença
Manual Diagnóstico e Estatístico de Transtornos Mentais
Feminino
Seres Humanos
Masculino
Meia-Idade
Avaliação de Resultados (Cuidados de Saúde)
Pacientes Ambulatoriais/psicologia
Transtornos Psicóticos/diagnóstico
Transtornos Psicóticos/epidemiologia
Transtornos Psicóticos/psicologia
Índice de Gravidade de Doença
Apoio Social
Ideação Suicida
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1111/bdi.12486


  8 / 22429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29419677
[Au] Autor:Chu WM; Ho HE; Wang JD; Chan WC; Liou YS; Ho WC; Hu SY; Tsan YT
[Ad] Endereço:Institute of Medicine, Chung Shan Medical University, Taichung.
[Ti] Título:Risk of major comorbidities among workers with hemophilia: A 14-year population-based study.
[So] Source:Medicine (Baltimore);97(6):e9803, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Multiple comorbidities, especially musculoskeletal dysfunction and cerebrovascular disease, remain barriers to normal social participation among persons with hemophilia (PWH). However, the relative health effects of such comorbidities on workers with hemophilia have seldom been explored. In this study, we investigated the incidence of comorbidities and their risk factors among workers with hemophilia.The study compared the incidence and risk factors of the major comorbidities of 411 workers with hemophilia enrolled in Taiwan's National Health Insurance Research Database between 1997 and 2010 with an age- and sex-matched general population.Compared with the general population, workers with hemophilia had higher risks for hemorrhagic stroke, arthritis/arthropathy, and knee/hip replacement among workers with hemophilia after multivariate adjustment, with hazard ratios (95% CI) of 4.60 (2.81-7.53), 4.03 (3.34-4.87), and 1.29 (1.10-1.41), respectively.Disorder of joints, hemophilia-related arthritis/arthropathy, hemorrhagic stroke, and knee/hip replacement remain significant comorbidities among workers with hemophilia, which will result in increased social burden. Policymakers and employers should apply appropriate interventions to help prevent productivity losses, reduced workforce participation, sick leave, and work disability among hemophilia workers.
[Mh] Termos MeSH primário: Transtornos Cerebrovasculares/epidemiologia
Hemofilia A/epidemiologia
Doenças Musculoesqueléticas/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Comorbidade
Efeitos Psicossociais da Doença
Bases de Dados Factuais/estatística & dados numéricos
Feminino
Seres Humanos
Incidência
Estudos Longitudinais
Masculino
Meia-Idade
Política Pública
Fatores de Risco
Taiwan/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180209
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009803


  9 / 22429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29385989
[Au] Autor:Giocanti-Aurégan A; Chbat E; Darugar A; Morel C; Morin B; Conrath J; Devin F
[Ad] Endereço:Department Ophthalmology, Avicenne Hospital, DHU Vision and Handicaps, 125 rue de Stalingrad, 93000, Bobigny, France. audreygiocanti@yahoo.fr.
[Ti] Título:Influence of new societal factors on neovascular age-related macular degeneration outcomes.
[So] Source:BMC Ophthalmol;18(1):22, 2018 Feb 01.
[Is] ISSN:1471-2415
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: To assess the impact of unstudied societal factors for neovascular age-related macular degeneration (nAMD) on functional outcomes after anti-VEGFs. METHODS: Charts of 94 nAMD patients treated in the Monticelli-Paradis Centre, Marseille, France, were reviewed. Phone interviews were conducted to assess societal factors, including transportation, living status, daily reading and social security scheme (SSS). Primary outcome was the impact of family support and disease burden on functional improvement in nAMD. RESULTS: Between baseline and month 24 (M24), 42.4% of the variability in best-corrected visual acuity (BCVA) was explained by the cumulative effect of the following societal factors: intermittent out-patient follow-up, marital status, daily reading, transportation type, commuting time. No isolated societal factor significantly correlated with ETDRS BCVA severity at M24. A trend to correlation was observed between the EDTRS score at M24 and the SSS (P = 0.076), economic burden (P = 0.075), time between diagnosis and treatment initiation (P = 0.070). A significant correlation was found for the disease burdensome on the patient (P = 0.034) and low vision rehabilitation (P = 0.014). CONCLUSIONS: Societal factors could influence functional outcomes in nAMD patients treated with anti-VEGFs. They could contribute to the healing process or sustain disease progression.
[Mh] Termos MeSH primário: Efeitos Psicossociais da Doença
Cobertura do Seguro
Qualidade de Vida/psicologia
Degeneração Macular Exsudativa/economia
Degeneração Macular Exsudativa/psicologia
[Mh] Termos MeSH secundário: Idoso
Inibidores da Angiogênese/administração & dosagem
Feminino
Seres Humanos
Injeções Intravítreas
Masculino
Ranibizumab/administração & dosagem
Estudos Retrospectivos
Fator A de Crescimento do Endotélio Vascular/antagonistas & inibidores
Baixa Visão/reabilitação
Acuidade Visual/fisiologia
Degeneração Macular Exsudativa/tratamento farmacológico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Angiogenesis Inhibitors); 0 (VEGFA protein, human); 0 (Vascular Endothelial Growth Factor A); ZL1R02VT79 (Ranibizumab)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180202
[St] Status:MEDLINE
[do] DOI:10.1186/s12886-018-0690-9


  10 / 22429 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28449892
[Au] Autor:Black J; Reaven NL; Funk SE; McGaughey K; Ohayon MM; Guilleminault C; Ruoff C
[Ad] Endereço:Stanford University, Palo Alto, CA, USA; Jazz Pharmaceuticals, Palo Alto, CA, USA. Electronic address: jedblack@stanford.edu.
[Ti] Título:Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study.
[So] Source:Sleep Med;33:13-18, 2017 May.
[Is] ISSN:1878-5506
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE/BACKGROUND: The objective of this study was to evaluate medical comorbidity patterns in patients with a narcolepsy diagnosis in the United States. PATIENTS/METHODS: This was a retrospective medical claims data analysis. Truven Health Analytics MarketScan® Research Databases were accessed to identify individuals ≥18 years of age with ≥1 diagnosis code for narcolepsy (International Classification of Diseases (ICD)-9, 347.0, 347.00, 347.01, 347.1, 347.10, or 347.11) continuously insured between 2006 and 2010, and controls without narcolepsy matched 5:1 on age, gender, region, and payer. Narcolepsy and control subjects were compared for frequency of comorbid conditions, identified by the appearance of >1 diagnosis code(s) mapped to a Clinical Classification System (CCS) level 1 category any time during the study period, and on specific subcategories, including recognized narcolepsy comorbidities of obstructive sleep apnea (OSA) and depression. RESULTS: The final study group included 9312 subjects with narcolepsy and 46,559 controls (each group: average age, 46.1 years; 59% female). As compared with controls, patients with narcolepsy showed a statistically significant excess prevalence in all the CCS multilevel categories, the only exceptions being conditions originating in the perinatal period and pregnancy/childbirth complications. The greatest excess prevalence in the narcolepsy cohort was seen for mental illness (31.1% excess prevalence; odds ratio (OR) 3.8, 95% confidence interval (CI) 3.6, 4.0), followed by diseases of the digestive system (21.4% excess prevalence; OR 2.7, 95% CI 2.5, 2.8) and nervous system/sense organs (excluding narcolepsy; 20.7% excess prevalence; OR 3.7, 95% CI 3.4, 3.9). CONCLUSIONS: In this claims analysis, a narcolepsy diagnosis was associated with a wide range of comorbid medical illness claims, at significantly higher rates than matched controls.
[Mh] Termos MeSH primário: Comorbidade/tendências
Efeitos Psicossociais da Doença
Narcolepsia/complicações
Narcolepsia/diagnóstico
[Mh] Termos MeSH secundário: Adulto
Bases de Dados Factuais
Depressão/complicações
Depressão/epidemiologia
Feminino
Seres Humanos
Revisão da Utilização de Seguros
Masculino
Meia-Idade
Narcolepsia/epidemiologia
Polissonografia/métodos
Prevalência
Estudos Retrospectivos
Apneia Obstrutiva do Sono/complicações
Apneia Obstrutiva do Sono/epidemiologia
Apneia Obstrutiva do Sono/fisiopatologia
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE



página 1 de 2243 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde